2-氯-5'-氟-2'-羟基-苯乙酮 | 2002-75-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-氯-5'-氟-2'-羟基-苯乙酮
• 中文别名: 2-氯-1-(5-氟-2-羟基苯基)乙烷-1-酮
• 英文名称: <5-Fluor-2-hydroxy-phenyl>-chlormethyl-keton
• 英文别名: 2-chloro-1-(5-fluoro-2-hydroxy-phenyl)-ethanone；2-Chloro-5'-fluoro-2'-hydroxy-acetophenone；2-chloro-1-(5-fluoro-2-hydroxyphenyl)ethanone
• CAS: 2002-75-7
• 化学式: C₈H₆ClFO₂
• mdl: MFCD11857873
• 分子量: 188.586
• InChiKey: MXQGROLAGNLEHA-UHFFFAOYSA-N

物化性质

• 溶解度：
  可溶于氯仿、可溶于二氯甲烷、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2914700090

反应信息

• 作为反应物：
  描述：

  2-氯-5'-氟-2'-羟基-苯乙酮 在 sodium acetate 作用下， 以 甲醇 为溶剂， 反应 2.0h， 生成 5-氟苯并呋喃-3(2H)-酮
  参考文献：
  名称：

  BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR

  摘要：

  公式（III）所代表的化合物或其药学上可接受的盐，并且公开了其在制备治疗与CRBN受体相关的疾病的药物中的应用。

  公开号：

  EP4043455A1
• 作为产物：
  描述：

  2-chloro-1-(5-fluoro-2-methoxyphenyl)ethanone 在 aluminum (III) chloride 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 生成 2-氯-5'-氟-2'-羟基-苯乙酮
  参考文献：
  名称：

  BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR

  摘要：

  公式（III）所代表的化合物或其药学上可接受的盐，并且公开了其在制备治疗与CRBN受体相关的疾病的药物中的应用。

  公开号：

  EP4043455A1

文献信息

• Process for preparation of racemic Nebivolol
  申请人：Bader Thomas

  公开号：US20070149612A1

  公开（公告）日：2007-06-28

  A process of making racemic [2S*[R*[R*[R*]]]] and [2R*[S*[S*[S*]]]]-(±)α,α′-[iminobis(methylene)]bis[6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol] of the compound of the formula (I) and its pure [2S*[R*[R*[R*]]]]- and [2R*[S*[S*[S*]]]]-enantiomer compounds and pharmaceutically acceptable salts thereof.

  将化合物的立体异构体制备成racemic [2S*[R*[R*[R*]]]]和[2R*[S*[S*[S*]]]]-(±)α,α′-[iminobis(methylene)]bis[6-氟-3,4-二氢-2H-1-苯并吡喃-2-甲醇]的过程，以及其纯[2S*[R*[R*[R*]]]]-和[2R*[S*[S*[S*]]]]-对映体化合物及其药用可接受的盐。
• [EN] NEW PROCESS FOR THE PREPARATION OF RACEMIC ([2S[2R*[R[R*]]]] and ([2R[2S*[S[S*]]]]-(±)- alpha,alpha' -[imino-bis(methylene)]bis[6-fluoro­chroman-2-methanol] AND ITS PURE [2S[2R*[R[R*]&<br/>[FR] NOUVEAU PROCEDE DE PREPARATION DE ([2S[2R*[R[R*]]]] ET ([2R[2S*[S[S*]]]]-(+/-)- 20040521US4654362AVAN LOMMEN GUY R E [BE], et al198703311528DA1DAJ. HENDRICKX ET AL.: "LOCATION OF THE OH FUNCTIONS IN HYDROXYLATED METABOLITES OF NEBIVOLOL", JOURNAL OF CHROMATOGRAPHY A, vol. 729, no. 1+2, 1996, GB, pages 341 - 354, XP002270638J. HENDRICKX ET AL.LOCATION OF THE OH FUNCTIONS IN HYDROXYLATED METABOLITES OF NEBIVOLOLJOURNAL OF CHROMATOGRAPHY AGB19967291+2341354353VA1,54,55A
  申请人：EGYT GYOGYSZERVEGYESZETI GYAR

  公开号：WO2004041805A1

  公开（公告）日：2004-05-21

  Process for the preparation of racemic ([2S[2R*[R[R*]]]]- and ([2R[2S*[S[S*]]]]-(±)- α,α' -[imino-bis(methylene)]bis[6-fluoro­chroman-2-methanol] of the compound of the formula (I) and its pure ([2S[2R*[R[R*]]]]- and ([2R[2S*[S[S*]]]]- enantiomer compounds characterized in that the products are prepared from 4-­fluoro-phenole or 4-fluoro-anisole via crystalline, optically active intermediates.

  用于制备化合物（I）的混合对映体（[2S[2R*[R[R*]]]]-和([2R[2S*[S[S*]]]]-(±)- α,α' -[亚胺-双(亚甲基)]双[6-氟基-色苷-2-甲醇]的过程及其纯度（[2S[2R*[R[R*]]]]-和([2R[2S*[S[S*]]]]-对映体化合物的特征在于所述产物是从4-氟苯酚或4-氟苯甲醚经过结晶的、具有光学活性的中间体制备而成。
• PROCESS FOR PREPARATION OF RACEMIC NEBIVOLOL
  申请人：Bader Thomas

  公开号：US20090048457A1

  公开（公告）日：2009-02-19

  A process of making racemic [2S*[R*[R*[R*]]]] and [2R*[S*[S*[S*]]]]-(±)α,α′-[iminobis(methylene)]bis[6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol] of the compound of the formula (I) and its pure [2S*[R*[R*[R*]]]]- and [2R*[S*[S*[S*]]]]-enantiomer compounds and pharmaceutically acceptable salts thereof.

  制备(±)α,α′-[亚氨基双(亚甲基)]双[6-氟-3,4-二氢-2H-1-苯并吡喃-2-甲醇]的外消旋体[2S*[R*[R*[R*]]]]和[2R*[S*[S*[S*]]]]的过程，以及该化合物的纯[2S*[R*[R*[R*]]]]-和[2R*[S*[S*[S*]]]]-对映体化合物及其药学上可接受的盐。
• [EN] BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR<br/>[FR] COMPOSÉ BICYCLIQUE QUI AGIT COMME RÉGULATEUR DE LA PROTÉINE CRBN<br/>[ZH] 作为CRBN蛋白调节剂的双并环类化合物
  申请人：MEDSHINE DISCOVERY INC

  公开号：WO2021047674A1

  公开（公告）日：2021-03-18

  一种式(III)所示化合物或其药学上可接受的盐，并公开了其在制备治疗与CRBN受体相关疾病药物中的应用。
• Structure-Based Design Leads to the Identification of Lithium Mimetics That Block Mania-like Effects in Rodents. Possible New GSK-3β Therapies for Bipolar Disorders
  作者：Alan P. Kozikowski、Irina N. Gaisina、Hongbin Yuan、Pavel A. Petukhov、Sylvie Y. Blond、Allison Fedolak、Barbara Caldarone、Paul McGonigle

  DOI：10.1021/ja068969w

  日期：2007.7.1

  More than two million American adults, or approximately one percent of the population 18 years or older, suffer from bipolar disorder. Current treatments include the so-called "mood stabilizers," lithium and valproic acid. Both are relatively dated drugs that are only partially effective and produce various undesirable side effects including weight gain. Based upon continued efforts to understand the molecular target for lithium, it now appears that specific inhibitors of the enzyme glycogen synthase kinase-3 beta (GSK-3 beta) may mimic the therapeutic action of mood stabilizers and might therefore allow for the design of improved drugs for treating patients with bipolar disorder as well as certain neurodegenerative disorders. Furthermore, the pro-apoptotic properties of the GSK-3 enzyme suggest the possible use of such inhibitors as neuroprotective agents. In fact, neuroprotection may contribute to the treatment of mood disorders. The present chemistry, modeling, and biology efforts have identified 3-benzofuranyl-4-indolylmaleimides as potent and relatively selective GSK-3 beta inhibitors. The best ligand in this series (having a K-i value of 4.6 nM against GSK-3 beta) was studied in a novel mouse model of mania that has recently been validated with several clinically effective mood stabilizers. This study presents the first demonstration of the efficacy of a GSK-3 beta inhibitor in this mouse model of mania. Selective brain penetrable GSK-3 ligands like those described herein become valuable research tools in better defining the role of this multifaceted kinase in both physiological and pathophysiological events.